Every 8-K that EMMAUS LIFE SCIENCES INC (EMMA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EMMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EMMA filings page.
Emmaus Life Sciences, Inc. reported sharply improved results for the three and six months ended June 30, 2026, driven by a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. Net revenues for the quarter rose 124% to $6.3 million from $2.8 million a year earlier, primarily from recognition of upfront and royalty revenue under the NIT license, partly offset by lower direct Endari sales. Total operating expenses fell to $2.1 million from $3.0 million, mainly due to transferring the sales force to NIT, resulting in income from operations of $3.8 million versus a $0.4 million loss.
Quarterly net income was $1.3 million, or $0.02 per basic share, compared with a net loss of $1.1 million, or ($0.02) per share in 2025. For the six-month period, net revenues were $8.3 million and the company recorded a net loss of $2.0 million, improved from a $3.5 million loss a year earlier. Cash and cash equivalents were $2.8 million at June 30, 2026, up from $2.1 million at December 31, 2025. The balance sheet shows total assets of $16.4 million against total liabilities of $82.5 million, resulting in a stockholders’ deficit of $66.2 million. The company also references previously disclosed doubt about its ability to continue as a going concern in its risk factors.
Emmaus Life Sciences reported first-quarter 2026 results showing lower revenue but reduced operating expenses. Net revenues for the three months ended March 31, 2026 were $2.0 million, down 18% from $2.4 million a year earlier, mainly from a 33% decline in U.S. sales amid generic L-glutamine competition, partly offset by a 446% increase in sales in the MENA region.
Total operating expenses fell to $2.6 million from $3.2 million, improving loss from operations to $0.8 million compared with $1.0 million. However, higher interest and derivative-related costs drove other expense up to $2.5 million, increasing net loss to $3.3 million, or $0.05 per share, versus $2.3 million, or $0.04 per share. Cash and cash equivalents were $1.1 million at March 31, 2026, with total liabilities of $86.6 million and a stockholders’ deficit of $67.9 million.
Emmaus Life Sciences, Inc. appointed Henry H. Du to its Board of Directors by written consent on April 16, 2026, filling the vacancy created by the recent resignation of Jon Kuwahara. He is also expected to replace Mr. Kuwahara as the sole member of the Board’s Audit Committee.
Mr. Du, age 48, is Vice President – Finance Accounting and interim Chief Financial Officer of Alpha Cognition, Inc., a biopharmaceutical company, and is a Certified Public Accountant with a Bachelor of Arts degree from Claremont McKenna College. Emmaus states there are no family relationships or related-party transactions requiring disclosure, and that he will be compensated like its other directors.
Emmaus Life Sciences, Inc. reported that director Jon Kuwahara resigned from its board. The resignation was dated April 13, 2026 and becomes effective April 15, 2026. The company also identified a cover page interactive data file as Exhibit 104 embedded within the inline XBRL document.
Emmaus Life Sciences reported full-year 2025 results showing sharply lower sales but improved operating performance. Net revenue was $12.5 million, down 25% from $16.7 million in 2024, mainly due to U.S. competition from generic L-glutamine, partly offset by higher sales in the MENA region.
Total operating expenses fell 34% to $11.4 million from $17.3 million, turning a $0.2 million income from operations versus a $1.9 million operating loss a year earlier. However, other expense rose to $7.5 million from $4.5 million, driven by higher loss on debt extinguishment and interest expense and lower gains on restructured debt.
Emmaus recorded a 2025 net loss of $7.2 million (or $0.12 per share) compared with a $6.5 million net loss (or $0.10 per share) in 2024. At December 31, 2025, cash and equivalents were $2.1 million versus $1.4 million a year earlier, while total liabilities were $85.0 million and stockholders’ deficit was $63.6 million. Management is shifting U.S. strategy through a license and exclusive distribution arrangement with NeoImmuneTech and emphasizes international growth for Endari.
Emmaus Life Sciences has entered into an Exclusive Supply Agreement with NeoImmuneTech (NIT), building on a prior license that grants NIT exclusive rights to market and distribute Endari for sickle cell disease in the U.S., its territories and possessions, and Canada.
The new agreement provides that, once the License Agreement’s “Effective Date” occurs, Emmaus will supply Endari and any generic equivalents exclusively to NIT, and NIT will, with limited exceptions, purchase all of its product requirements from Emmaus at a price equal to Emmaus’ production cost plus a specified double‑digit percentage margin.
The Effective Date depends on NIT obtaining required regulatory approvals and other conditions, and may never be reached. Either party may terminate the License Agreement if the Effective Date has not occurred by October 1, 2026, unless the delay results from wrongful acts by Emmaus.
Emmaus Life Sciences entered into a License and Exclusive Distribution Agreement with NeoImmuneTech (NIT) giving NIT exclusive rights to market, sell, and distribute Endari and its generic equivalents for sickle cell disease in the U.S., its territories, and Canada. In return, Emmaus receives an upfront payment and ongoing royalties on NIT’s product sales.
Once the agreement’s “Effective Date” occurs, Emmaus will also become NIT’s exclusive supplier of Endari for this use and region at a price based on Emmaus’ production cost plus an agreed margin. The Effective Date depends on NIT obtaining required regulatory approvals and other conditions, and the agreement can be terminated if these are not met by October 1, 2026. If NIT does not achieve specified minimum annual sales after the Effective Date, its rights become nonexclusive, while Emmaus keeps all Endari rights outside this disease area and territory.
Emmaus Life Sciences, Inc. entered into an exchange agreement with a single noteholder on December 17, 2025. The company agreed to issue 6,332,692 shares of common stock valued at approximately $0.38 per share and a new convertible promissory note with a principal amount of $600,000. In return, the holder surrendered for cancellation an outstanding convertible promissory note with a principal amount of $3,000,000 that was already due and payable.
The cancelled note carried 10% annual interest and was convertible at $0.13 per share. The new note also bears 10% annual interest and is initially convertible at $0.01 per share, subject to quarterly reset to the average VWAP if that is lower, and to adjustment for stock splits and similar events. The principal on the new note is due on demand, and no additional cash consideration was exchanged. The securities will be issued without registration in reliance on the Section 3(a)(9) exemption.
Emmaus Life Sciences, Inc. reported a board change, disclosing that director Ian Zwicker resigned from the company’s board of directors on December 15, 2025, with the resignation to take effect on December 31, 2025. The filing does not describe any related financial effects or changes to the company’s operations, focusing solely on this governance update. Emmaus remains a Delaware corporation headquartered in Torrance, California, and the report was signed by Chairman and Chief Executive Officer Willis Lee.
Emmaus Life Sciences, Inc. filed a current report to note that it issued a press release on November 14, 2025 announcing its results of operations and financial condition for the three months ended September 30, 2025. The company attached this press release as Exhibit 99.1 and incorporated it by reference. The company also clarified that the earnings information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities filings.